Form 4: Neumora CEO Sells Shares for Tax Obligations

Neumora Therapeutics CEO Paul L. Berns sold 9,819 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Paul L. Berns, Chief Executive Officer and Chairman of the Board of Neumora Therapeutics, Inc. (NMRA), reported a transaction on February 17, 2026.
• Berns disposed of 9,819 shares of Neumora Therapeutics Common Stock.
• The shares were sold at a weighted average price of $3.5094 per share, with individual trades ranging from $3.48 to $3.545.
• The purpose of this sale was to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
• Following this transaction, Berns directly beneficially owns 7,395,185 shares of Common Stock.
• Additionally, Berns indirectly beneficially owns 133,097 shares each through the LULU TRUST OF 2024 FBO AB, LULU TRUST OF 2024 FBO OB, and LULU TRUST OF 2024 FBO HB.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transaction is a routine sale to cover tax obligations from RSU vesting, which is a common practice for executives and does not indicate a change in the company's fundamentals or management's confidence.

Positives

• The underlying event, the vesting of restricted stock units, indicates that executive compensation is being realized, which is a standard component of executive incentive plans.

Negatives

• No significant negatives are directly associated with this routine tax-related sale.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that insider sales to cover tax withholding obligations upon the vesting of restricted stock units are a common and routine practice for executives across various industries. This type of transaction is generally not indicative of a change in management's outlook on the company's prospects or a lack of confidence, but rather a standard mechanism for managing compensation and tax liabilities.

Comparison to Industry Standards

• This transaction aligns with standard executive compensation practices observed in the biotechnology and pharmaceutical sectors, where restricted stock units (RSUs) are a prevalent form of equity compensation.
• The sale of shares to cover tax obligations upon RSU vesting is a routine financial event for executives, comparable to practices at companies like Pfizer, Moderna, or Johnson & Johnson, where executives frequently engage in similar tax-related sales without signaling a shift in company fundamentals.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine tax-related sale and does not reflect a change in the company's operational or financial health.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

The transaction reported is a routine sale of shares by the CEO to cover tax withholding obligations associated with the vesting of restricted stock units. This is a common and expected event for executives receiving equity compensation and does not provide new information that would alter the fundamental investment thesis for Neumora Therapeutics. Therefore, a 'hold' recommendation is appropriate as there is no indication of a change in company performance or management's long-term outlook.

Keywords

Neumora Therapeutics, NMRA, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, CEO, Director